Gail J Roboz
Affiliation: Cornell University
- Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz
Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 43:1951-5. 2002..In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile...
- Novel approaches to the treatment of acute myeloid leukemiaGail J Roboz
Weill Medical College of Cornell University, New York, NY 10021, USA
Hematology Am Soc Hematol Educ Program 2011:43-50. 2011....
- Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxideGail J Roboz
Gail J Roboz, Ellen K Ritchie, Tania J Curcio, Eric J Feldman, and Paul D Kligfield, Weill Medical College of Cornell University and New York Presbyterian Hospital Michael Samuel, Montefiore Medical Center and Albert Einstein College of Medicine Juliette L Provenzano Gober, New York University, New York, NY Rebecca F Carlin, Greater Baltimore Medical Center, Baltimore, MD and Leanne Gale, University of Pennsylvania, Philadelphia, PA
J Clin Oncol 32:3723-8. 2014..The objective of this study was to characterize the prevalence, management, and clinical consequences of QT prolongation in a large cohort of patients treated with ATO...
- International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz
Gail J Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital Todd Rosenblat, Columbia University Medical Center, New York, NY Martha Arellano, Winship Cancer Institute at Emory University Scott R Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA Jessica K Altman, Francis J Giles, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Casey O Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut Lévêque, Pessac Norbert Vey, L Institut Paoli Calmettes, Marseilles, France Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom Tove Flem Jacobsen, Athos Gianella Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway
J Clin Oncol 32:1919-26. 2014....
- Current treatment of acute myeloid leukemiaGail J Roboz
Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10065, USA
Curr Opin Oncol 24:711-9. 2012..The objectives of this review are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leukemia (AML), excluding acute promyelocytic leukemia...
- Are low-intensity induction strategies better for older patients with acute myeloid leukemia?Gail J Roboz
Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States
Leuk Res 36:407-12. 2012..There were no differences in 30- or 60-day mortality between the two groups...
- Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemiaGail J Roboz
Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
Cancer 113:2504-11. 2008..In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged >or=60 years with AML...
- Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndromeGail J Roboz
Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Res 35:522-5. 2011..Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments...
- Acute myeloid leukemia stem cells: seek and destroyGail J Roboz
Weill Medical College of Cornell University, The New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
Expert Rev Hematol 2:663-72. 2009..This review will describe bench and translational research in LSCs and discuss how the data should be used to change the direction of developmental therapeutics and clinical trials in AML...
- Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemiaGail J Roboz
Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Hematol 45:S22-4. 2008..Manuscript has been accepted for publication...
- Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz
Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Res 31:1141-4. 2007..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting...
- Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz
Leukemia Program, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, NY, USA
Leukemia 20:952-7. 2006..In conclusion, the MTD of PTK/ZK is 750 mg orally b.i.d. The drug is generally well tolerated and can be given in combination with chemotherapy for patients with MDS and AML...
- Treatment of acute myeloid leukemia in older patientsGail J Roboz
Weill Medical College of Cornell University and The New York Presbyterian Hospital, 520 East 70th Street, Starr 340A, New York, NY 10021, USA
Expert Rev Anticancer Ther 7:285-95. 2007..The role of hematopoietic stem cell transplantation in older patients is under investigation. All patients over 60 years of age with acute myeloid leukemia should be encouraged to participate in a clinical trial if possible...
- Hematopoietic growth factors in myelodysplastic syndromesVictoria S Blinder
Weill Medical College of Cornell University, Starr Building, Room 340A, 520 East 70th Street, New York, NY 10021, USA
Curr Hematol Rep 2:453-8. 2003..This paper reviews the role of hematopoietic growth factors in the treatment of MDS...
- Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz
Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
J Clin Oncol 25:10-5. 2007....
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLJoseph M Scandura
Leukemia Program, Weill Cornell Medical College, New York, NY, USA
Blood 118:1472-80. 2011..We conclude that epigenetic priming of intensive chemotherapy can be safely delivered in an attempt to improve response rates. This trial was registered at www.clinicaltrials.gov as NCT00538876...
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaEllen K Ritchie
Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
Leuk Lymphoma 54:2003-7. 2013..7% with a median OS of 177 days. Extramedullary toxicity was mild and the regimen was well tolerated for ongoing post-remission, outpatient maintenance cycles. Responses were durable for over 1 year...
- Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza
St Vincent s Comprehensive Cancer Center, New York, NY, USA
Leuk Lymphoma 50:1336-44. 2009..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
- First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaEric J Feldman
Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
J Clin Oncol 29:979-85. 2011..This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351...
- A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore
Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
Biol Blood Marrow Transplant 12:868-75. 2006....
- Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemiaEric J Feldman
Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
J Clin Oncol 23:4110-6. 2005..In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)...
- Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)Amy E Dezern
a Department of Oncology, Sidney Kimmel Cancer Center, Baltimore, MD, USA
Leuk Lymphoma . 2016..3 months with DAC versus 17.9 months for AZA, p = .59). The biological reason for this variability is unclear, but may be a consequence of differences in cytidine deaminase activity between men and women...
- Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz
Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
Leuk Lymphoma 56:395-400. 2015..Due to the unpredictable nature of drug exposure, the sponsor decided to discontinue the study prior to reaching the maximum tolerated dose...
- Levels of care: defining best supportive care in elderly patients with acute myeloid leukemiaEllen K Ritchie
Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 10065, USA
Curr Hematol Malig Rep 5:95-100. 2010..Because it has never been shown that BSC as a sole therapeutic approach is kinder, less expensive, or better for older AML patients, it should be reserved for select clinical situations...
- Standardizing the initial evaluation for myelodysplastic syndromesDanielle Marshall
Department of Medicine, Weill Medical College of Cornell University, 515 E 71st Street, S Building, Room S262, New York, NY, 10021, USA
Curr Hematol Malig Rep 8:361-9. 2013....
- Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignanciesMichael J Satlin
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Leuk Lymphoma 54:799-806. 2013..New diagnostic, therapeutic and preventive strategies for CRE infections in this vulnerable population are needed...
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz
Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
Future Oncol 12:293-302. 2016..This trial will investigate whether CC-486 maintenance can prolong remission and improve survival for older patients with AML. ..
- Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha
Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, United States
Leuk Res 41:43-7. 2016..1 vs. 14.4 months, respectively, p=.04). In conclusion, patients treated with HMAs who achieves CR after a SD status had longer survival with continuous treatment after 6 months...
- Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner
a Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
Leuk Lymphoma 56:2543-51. 2015..In this phase I study, although gastrointestinal adverse events were common, significant clinical activity with lestaurtinib was observed (ClinicalTrials.gov identifier: NCT00668421). ..
- Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendiumGail J Roboz
Memorial Sloan Kettering Cancer Center, New York, NY
Clin Adv Hematol Oncol 12:8-18, 1. 2014..This clinical roundtable monograph features case studies that illustrate important points in the management of adult patients with relapsed/refractory ALL...
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz
Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Blood 113:3938-46. 2009....
- Pregnancy in a woman with chronic neutrophilic leukemiaJolyn Taylor
Department of Obstetrics and Gynecology, New York Presbyterian Hospital Weill Cornell Medical Center, New York, New York 10065, USA
Obstet Gynecol 121:457-60. 2013..Chronic neutrophilic leukemia is a rare myeloproliferative disorder in women of reproductive age...
- Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles
Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
Leuk Res 27:1091-6. 2003..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
- Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts
Massey Cancer Center, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA 23298, USA
Clin Cancer Res 12:5809-16. 2006..We undertook a phase I study to identify appropriate schedules and doses of bryostatin 1 and fludarabine to be used in phase II studies...
- PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles
The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 31:891-7. 2007..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
- Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseFrancois Guilhot
Clinical Research Centre, Centre Hospitalier et Universitaire La Miletrie, Poitiers, France
Blood 109:4143-50. 2007..Further follow-up is warranted. This trial was registered at www.clinicaltrials.gov as #CA180005...